Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you research heart damage from cancer drugs or regulatory science approaches to drug safety, the FDA has dedicated funding for applied research that could accelerate clinical impact.
Report stale or inaccurate summary
What this is
The FDA is seeking research proposals on regulatory science approaches to understand, evaluate, and treat cardiotoxicity—heart damage caused by cancer treatments. This is an applied research opportunity aimed at improving drug safety and patient outcomes by developing better methods to detect, predict, and manage cardiac side effects from oncology drugs. The program is particularly suited for researchers with expertise in cardiology, drug safety, clinical evaluation, or regulatory pathways in cancer medicine.
Who can apply
Eligibility criteria are not specified in the provided text; applicant types are listed as unspecified. Check the full announcement or FDA website for details on whether domestic institutions, small businesses, non-profits, or individuals can apply.
Topics: cardiotoxicity · oncology · regulatory science · drug safety · cardiac side effects
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.